Meeting
2018 ASCO Annual Meeting
The population-based impact of adjuvant chemotherapy (CTx) on outcomes in AJCC6 stage IB non-small cell lung cancer (NSCLC).
Authors
Rahul Krishan Arora
Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada
Rahul Krishan Arora , Amanda Williams Gibson , D. Gwyn Bebb , Winson Y. Cheung
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 36, 2018 (suppl; abstr 8523)
DOI
10.1200/JCO.2018.36.15_suppl.8523
Abstract #
8523
Poster Bd #
129
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes predicts survival after immune checkpoint inhibitor therapy across multiple cancer types.
First Author: Jeanne Shen
Poster
2020 ASCO Virtual Scientific Program
Role of adjuvant chemotherapy in patients with pathological stage I NSCLC with high-risk features.
First Author: Lubina Arjyal
Poster
2019 ASCO Annual Meeting
A comparative analysis of survival in patients with non-small cell lung cancer with brain metastases receiving intracranial radiation with and without immunotherapy.
First Author: Sunita Patruni
Poster
2018 ASCO Annual Meeting
Impact of somatic mutations on recurrence free survival (RFS) and overall survival (OS) for resected non-small cell lung cancer (NSCLC): results from the Japan Molecular Epidemiology for lung cancer study (JME).
First Author: Akihiro Tamiya